Abstract

Der 25. Manfred Donike Workshop für Dopinganalyse fand vom 25. Februar bis 2. März 2007 in Köln statt. Der im selben Jahr veröffentlichte Kongressband enthält die folgenden Beiträge: 1. R.I.G. Holt, I. Erotokritou-Mulligan, D. Cowan, C. Bartlett, E.E. Bassett, E.E. Muller, A. Sartorio, P.H. Sönksen: The GH-IGF-2012 project: the use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: intra-individual variation of IGF-I and P-III-P; 2. M. Kohler, K. Püschel, W. Schänzer, M. Thevis: Mass spectrometric identification of human pituitary growth hormone variants; 3. R. Kazlauskas: Supplements & WADA List; 4. P. Van Eenoo, L. Lootens, W. Van Thuyne, K. Deventer, O. Pozo-Mendoza, F.T. Delbeke: Results of several (small) research projects at DoCoLab in 2006; 5. M. Mazzarino, F. Botrè: How safe are our internal procedures? Some preliminary experimental evidence on the problem of "lab-oriented" potential masking agents; 6. P. Van Eenoo, A. Spaerkeer, F.T. Delbeke: Measurement uncertainty - a practical top-down approach; 7. M. Thevis, J.A. Loo, R.R. Ogorzalek Loo, W. Schänzer: Recommended criteria for the mass spectrometric identification of target peptides and proteins (< 8 kDa) in sports drug testing; 8. A. Kazlauskas: Being expert in the 21st century; 9. E. Grobbelaar, P.J. van der Merwe, J.H.W. Potgieter: Urinary concentrations of inhaled and orally administered Salbutamol; 10. U. Mareck, N. Haenelt, M.K. Parr, S. Guddat, A. Thomas, M. Thevis, W. Schänzer: Direct quantification of Salbutamol in human urine by means of LC-MS/MS; 11. M.K. Parr, A. Orlovius, S. Guddat, M. Gütschow, M. Thevis, W. Schänzer: Sulfoconjugates of heavy volatile nitrogen containing doping substances for improved LC-MS/MS screening; 12. R. Montes de Oca Porto, M.T. Correa Vidal, A. Rosado Pèrez, M. Granda Fraga: Confirmatory procedure of ephedrines by gas chromatography-mass spectrometry. Migration of the trimethylsilyl group in the N-acetyl-O-trimethylsilyl derivatives; 13. B. Vitoriano, X. de la Torre: Study of Clomiphene metabolism by LC/MS/MS; 14. M. Okano, A. Ikekita, M. Sato, S. Kageyama: Detection of Mepitiostane in doping analysis; 15. H. Geyer, U. Flenker, U. Mareck, P. Platen, T. Piper, A. Schmechel, Y. Schrader, M. Thevis, W. Schänzer: The detection of the misuse of testosterone gel; 16. M.K. Parr, G. Opfermann, T. Piper, N. Schlörer, G. Fußhöller, A. Thomas, M. Thevis, W. Schänzer: Characterisation of steroid metabolites recently detected in doping control analyses; 17. O.J. Pozo, K. Deventer, P. Van Eenoo, F.T. Delbeke: Endogenous interferences in the detection of anabolic steroids by liquid chromatography tandem mass spectrometry; 18. A. Leinonen, J. Apajalahti, T. Moisander, O. Siikanen, T. Kuuranne, M. Lauraeus: Experiments on production of "endogenous Boldenone"; 19. T. Piper, M. Hebestreit, U. Flenker, H. Geyer, W. Schänzer: A method to determine δ13CVPDB-values of trace amounts of Boldenone and its main metabolite; 20. Ying Zhang, G.L. Sacks, J.T. Brenna: Fast gas chromatography combustion isotope ratio mass spectrometry; 21. A. Cawley, R. Kazlauskas, G. Trout, A. George: Metabolie 13C fractionation: what it means for doping control; 22. A. Cawley, R. Kazlauskas, G. Trout, A. George, R. Weatherby, S. Marshall-Gradisnik: Compound specific detection of endogenous steroid abuse in athletes; 23. U. Flenker, F. Hülsemann, V. Gougoulidis, G. Sigmund, W. Schänzer: Elucidation of original and metabolic sources of ephedrines by stable isotope analysis; 24. A.I. Silva Junior, H.M.G. Pereira, A. Casilli, F.R. Aquino Neto: Analytical challenges in doping control: GC x GC: is it an option?; 25. W. Van Thuyne, P. Van Eenoo, F.T. Delbeke: Possibilities of SIM/scan analysis in doping control; 26. X. Kioussi, A. Fragkaki, A. Vonaparti, M. Stamou, M. Demesticha, E. Lyris, Y.S. Angelis, G. Tsoupras, B. Wuest, M.W.F. Nielen, I. Panderi, M. Koupparis, C. Georgakopoulos: Time-of-flight mass spectrometry: unification of analytical methods and preventive screening in doping control analysis; 27. J.O. Thörngren, F. Östervall, M. Garle: A new approach for screening, verifying and confirmation of prohibited doping substances; 28. O.J. Pozo, W. Van Thuyne, P. Van Eenoo, K. Deventer, F.T. Delbeke: Use of liquid chromatography tandem mass spectrometry (LC-MS/MS) and gas chromatography (GC-MS) in the detection of Fluoxymesterone metabolites; 29. M. Thevis, M. Kohler, W. Schänzer: Mass spectrometry of new growth promoting drugs: Hydantoin-derived selective androgen receptor modulators and growth hormone secretagogues; 30. R. Gutiérrez Gallego, A. Pinyot Comelles, Z. Nikolovski, J. Bosch, J. Segura: Growth hormone secretagogues; 31. J. Maurer, M. Kohler, W. Schänzer, M. Thevis: Identification of proteolytic enzymes in human urine; 32. A. Thomas, M. Thevis, P. Delahaut, A. Bosseloir, W. Schänzer: Identification and determination of degradation products of human insulin and its long acting synthetic analogues in urine by means of ESI-LC-MS/MS; 33. P. Desharnais, C. Ayotte: Towards the screening of urinary EPO by SDS-PAGE analysis; 34. P.E. Groleau, P. Desharnais, C. Ayotte: Characterization of glycopeptides released from pmol levels of recombinant erythropoietin by nanoflow HPLC-Chip electrospray ionization coupled to ion trap mass spectrometry; 35. C. Reichel: Identification of Zinc-alpha-2-glycoprotein binding to clone AE7A5 antihuman Epo antibody by means of nano-HPLC and high-resolution accurate mass ESI-MS/MS; 36. J. Segura, C. Fillat, D. Andreu, J. Llop, O. Millan, B.G. de la Torre, Z. Nikolovski, V. Gomez, N. Andreu, A. Pinyot, R. Castelo, J.D. Gispert, J.A. Pascual: Non invasive molecular imaging of gene expression potentially useful for doping control: pilot study in cells and animals; 37. G.J. Trout, M. Sultani, C. Goebel, C.J. Howe, R. Kazlauskas: Miscellaneous projects in sports drug testing at the National Measurement Institute, Australia, 2006 or, "an ASDTL Assortment"; 38. S: Hudson, S. Maynard, M. Harrison: Can multiple instrumental analyses be replaced by a single analysis?; 39. T.F.H. Bovee, J.C.W. Rijk, A.A.C.M. Peijnenburg, M.W.F. Nielen: A specific yeast androgen bioassay for the detection of androgens, anti-androgens and pro-androgens in supplements and urine; 40. M. Maatki, S. Bouabdallah, S. Kraiem, A. Toumi: Optimization and validation of analytical method for anabolic steroids in nutritional supplements by GC/MS; 41. A. Gotzmann, S.C. Voß, W. Schänzer: Abbott IMx® total ß-hCG-kit versus Roche Elecsys® hCG STAT-kit: validation and performance comparison; 42. R. Pootrakronchai, M. Kaewklum, P. Wilairat, T. Kusamran; T. Anukarahanonta: Method validation for d/l-isomers of methamphetamine and amphetamine by GC/MS; 43. M. Okano, M. Sato, A. Ikekita, S. Kageyama: A rapid ultra-performance liquid chromatography (UPLC™) /mass spectrometry- applications in doping control; 44. K. Deventer, O.J. Pozo, W. Van Thuyne, P. Van Eenoo, F.T. Delbeke: Screening and confirmation of ritalinic acid in urine by LC-MSn; 45. K. Koehler, H. Geyer, S. Guddat, A. Orlovius, M.K. Parr, M. Thevis, J. Mester, W. Schänzer: Sibutramine found in chinese herbal slimming tea and capsules; 46. P. Gärtner, K. Hofbauer, G. Gmeiner, T. Geisendorfer: Synthesis and characterization of a metabolite of Tamoxifen; 47. S. Jain, T. Kaur, R. Khanduja, S. Shweta, A. Beotra: Correlation of steroid profile data on GC-MSD with delta values on GC-IRMS after administration of testosterone preparations to healthy volunteers with low and high T/E ratio; 48. R. Picu, M. Zorio, M. Lamor: The influence of hCG administration on the steroidic profile; 49. J. Grosse, C. Rautenberg, L. Wassill, D. Ganghofner, D. Thieme: Degradation of doping-relevant steroids by Rh. erythropolis; 50. S. Torrado, M. Roig, M. Farré, J. Segura, R. Ventura: Metabolic profile in human urine after oral administration of 19-Norandrostenediol as a nutritional supplement; 51. G. Fußhöller, U. Mareck, A. Schmechel, W. Schänzer: Long-term detection of metandienone abuse by means of the new metabolite 17ß-hydroxymethyl-17α-methyl-18-norandrost-1,4,13-trien-3-one; 52. S. Guddat, W. Schänzer, P. Wachsmuth, M. Thevis: Doping control screening procedure for Trenbolone analogues in human urine byLC-(APCI)-MS/MS; 53. A. Leinonen, T. Kuuranne, T. Moisander, K. Rautava: Artificial urine as sample matrix for calibrators and quality controls in determination of testosterone to epitestosterone ratio; 54. Y. Dehnes, M. Borgen, P. Hemmersbach: Enzymatic digestion of EPO; 55. I. Holländer, I. Bajla, M. Minichmayr, G. Gmeiner, C. Reichel: GASepo: project summary 2004-2006; 56. A. Kniess, E. Ziegler, D. Thieme, R. K. Müller: A hGH application study: issues related to valid detection parameters; 57. H.A. Dimopoulou, T. Theodoridis, V. Galea, V. Christopoulou-Cokkinou, M.H. Spyridaki, CG. Georgakopoulos: ISO/IEC 17025 Sysmex R-500 hematology reticulocyte analyzer validation; 58. L. Avois, I. Bailloux, A. Desmarchelier, A. Lahaussois, N. Méchin, M. Saugy, J. de Ceaurriz: Synthetic glucocorticosteroids administration: urinary excretion of Triamcinolone acetonide; 59. M.T. Correa Vidal, D. Martinez, R. Montes de Oca, K. Alonso Pérez, M. Granda Fraga: Differences in urine excretion of Hydrocortisone (Cortisol) following two administration routes; 60. C. Bakkene, J. Henninge, I. Hullstein, P. Hemmersbach: Urinary levels of glucocorticoids resulting from different routes of administration; 61. W. Van Thuyne, F.T. Delbeke: Medication use in sports; 62. M. Plata Andrés, A. Frutos Sicilia, C. Turmo Blanco, J. Munoz-Guerra Revilla, A. F. Rodriguez Cano, C. Rodriguez Bueno: An information security management system for the doping control laboratory of Madrid: achieving ISO 27001:2005 standard; 63. S. Lüdke, M. Sauer, M. Paul, W. Schänzer: The Cologne Import Information System: a tool to highlight long term trends in the black market for drugs and doping substances. AGa und Inhaltsverzeichnis